WallStSmart

Concentra Group Holdings Parent, Inc. (CON)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 2378% more annual revenue ($56.69B vs $2.29B). NVS leads profitability with a 22.5% profit margin vs 8.7%. NVS trades at a lower P/E of 20.7x. CON earns a higher WallStSmart Score of 61/100 (C+).

CON

Buy

61

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 5.3Quality: 3.5
Piotroski: 2/9Altman Z: 1.26

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CON.

NVSSignificantly Overvalued (-50.3%)

Margin of Safety

-50.3%

Fair Value

$93.40

Current Price

$140.98

$47.58 premium

UndervaluedFair: $93.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CON2 strengths · Avg: 9.0/10
Return on EquityProfitability
41.9%10/10

Every $100 of equity generates 42 in profit

EPS GrowthGrowth
47.0%8/10

Earnings expanding 47.0% YoY

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

CON4 concerns · Avg: 2.5/10
Price/BookValuation
9.3x4/10

Trading at 9.3x book value

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.262/10

Distress zone — elevated risk

Debt/EquityHealth
4.491/10

Elevated debt levels

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CON

The strongest argument for CON centers on Return on Equity, EPS Growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : CON

The primary concerns for CON are Price/Book, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 4.49 is elevated, increasing financial risk.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

CON carries more volatility with a beta of 0.63 — expect wider price swings.

CON is growing revenue faster at 10.0% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CON scores higher overall (61/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Concentra Group Holdings Parent, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company strategically focused on acquiring and managing businesses across high-growth sectors, including healthcare, technology, and infrastructure. With a robust leadership team committed to operational excellence and innovation, Concentra actively seeks to optimize its portfolio through strategic investments and management practices. This proactive approach enables Concentra to effectively leverage emerging market trends and growth opportunities, making it a compelling choice for institutional investors seeking diversification in dynamic and high-potential markets.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?